The insider selling is routine and non-informative given the small dollar amounts relative to market cap and the presence of non-cash derivative exercises. No bearish signal is warranted. Monitor upcoming earnings (next 10-Q) for any guidance changes, but this cluster alone does not indicate material negative news.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 10 $160.86entry
- T+1 · 5mo ago +1.15%α −0.55% · $162.71
- T+5 · 5mo ago −2.76%α −6.19% · $156.42
- T+20 · 4mo ago +12.24%α +8.62% · $180.55
- T+60 · 2mo ago −1.56%α −8.14% · $158.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A cluster of insider selling at Neurocrine Biosciences over the past week totals $4.53M in open-market sales by four officers/directors, including the Chief Scientific Officer and Chief Human Resources Officer. The selling is modest relative to the $16.4B market cap (0.028%) and includes non-cash derivative exercises and gifts, suggesting liquidity-driven rather than informational selling.
Key Financial Metrics
Key Facts
- Four insiders sold a total of $4.53M in open-market sales over 7 days (May 29–June 5, 2026).
- Sales represent ~0.028% of NBIX's $16.4B market cap, well below the 0.1% materiality threshold.
- Director Sherwin exercised 30,000 options (non-cash) and sold 7,883 shares for $1.29M; the exercise price was $53.64, indicating routine option monetization.
- Chief Scientific Officer Onyia gifted 2,441 shares (non-cash), no economic signal.
- No 10b5-1 plan disclosures are present, but the pattern of option exercises and gifts alongside sales is consistent with routine portfolio management.
Financial Impact
Total insider sales of $4.53M, or 0.028% of market cap, immaterial relative to company size.
Risk Factors
- Insider selling could accelerate if the stock continues to trade near recent highs, but current volume is immaterial.
- No specific catalyst identified; the cluster is not predictive of near-term stock movement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1781041273939 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers